(NF) type 1, which are caused by genetic mutations of RET, VHL and NF-1, respectively. In 2000 and 2001, three genes, SDHB, SDHC, and SDHD, encoding subunits of the succinate dehydrogenase enzyme, a part of the mitochondrial respiratory chain, were identified as susceptibility genes for PCC and PGL [1] [2] [3] . Both SDHB (35.4kb, 8 exons) and SDHC (50.3kb, 6 exons) are located on chromosome 1 at 1p35 and 1q23, respectively. SDHD (8.9kb 4 exons) is located on 11q23. PCC and PGL caused by genetic mutation of one of these three genes are named as hereditary pheochromocytoma paraganglioma syndrome (HPPS). Among these, mutations of SDHB and SDHD play pivotal pathogenic roles in HPPS compared with those of SDHC [4, 6, 9] . An Italian study showed that genetic mutations account for approximately 30% of functional and non-functional cases of PCC and PGL, of which approximately 15% were recognized as Note and/or PGL who were surgically treated at Hokkaido University Hospital during [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] . We obtained written informed consent from all patients according to the medical ethics committee of Hokkaido University for the use of human materials for scientific purpose. Patients who presented with a head and neck or thoracic PGL were not included in this study. Four of the 18 patients had a family history of PCC or PGL, and two of them were parent and child suffered from VHL. Clinical and pathological characteristics of the 18 patients are shown in Table 1 .
We performed genetic sequencing of the 8 exons of SDHB and 4 exons of SDHD using tumor specimens. Genomic DNA was isolated by using the DNeasy Blood & Tissue Kit (QIAGEN, Tokyo, Japan). Each exon of the SDHB and SDHD genes was amplified using AmpliTaq Gold 360 Master Mix (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instruction. Briefly, PCR amplifications were performed in 20µL reactions and the conditions were as follows: initial denaturation at 95 °C for 9 min, then 35 cycles of denaturation at 95 °C for 15 sec, annealing at 51 °C for 30 sec, and extension at 72 °C for 30 sec, and a final extension at 72 °C for 7 min. The nucleotide sequences of the primers used are list-HPPS [4] . SDHA, encoding another subunit of the succinate dehydrogenase enzyme, lies on 5p15 and is composed of 15 exons spread over a genomic region of 38.4kb. Genetic mutation of SDHA causes Leigh syndrome, a subacute necrotizing encephalomyelopathy during infancy.
SDH mutations are widely distributed along the gene with no hot spots. To date, several studies in Western countries [4] [5] [6] [7] [8] [9] have revealed associations between mutated genes (genotype) and clinical characteristics (phenotype) of patients. Patients with mutation of SDHB show a high prevalence of abdominal PGL with malignant potential as the initial tumor. In contrast, those with SDHD mutation show multiple benign PGL lesions on the head and neck as the main tumor. However, there is no evidence as to whether these associations hold among Japanese cases. Since there are few reports on SDH mutations in HPPS in Asian countries [10, 11] , we analyzed SDHB and SDHD mutations in 18 Japanese patients diagnosed with PCC and/or PGL.
Patients and methods
This study included 18 Japanese patients with PCC Patients with a mutation in SDHB are known to have the following features. First, they have a high prevalence of abdominal PGL with malignant potential as the initial tumor. Second, patients typically show hypersecretion of noradrenaline and/or dopamine with lower secretion of adrenaline. This probably reflects reduced expression of phenylethanolamine -N -methyl -transferase, an enzyme that exists almost only in medullary chromaffin cells and converts noradrenaline to adrenaline. However, 10% of those tumors are biochemically silent so that diagnosis tends to be delayed by lack of symptoms until the tumor grows. Third, many patients with PGL clinically have no family history of PGL. A study in a Western country revealed that 90% (26 of 29) of patients with SDHB-mutated abdominal and thoracic PGL lacked a family history of PGL and all primary tumors but one originated from extra-adrenal locations [8] . As described above, PGL with SDHB mutations have been suggested to be primarily identified as an abdominal tumor with high malignant potential. Further, SDHB mutations are predictive of rapid metastatic spread and are associated with poor prognosis [14] . Therefore, long-term ined in Table 2 [1, 12] . Then, the PCR product was purified with QIA quick PCR Purification Kit (QIAGEN), and direct sequence analysis was performed with a Big Dye Terminator sequencing kit version 1.1 (Applied Biosystems), using the same primers on both strand. After direct sequence analysis, we determined the genetic mutation by sequencing of PCR products subcloned into pGEM®-T Easy Vector (Promega, Madison, WI, USA).
results and Discussion
We sequenced the SDHB and SDHD genes in 18 Japanese patients with PCC and/or PGL. A novel heterozygous nonsense mutation of CAG > TAG (Q168X) in the SDHB gene resulting in a glutamineto-stop substitution was identified (Fig. 1 ) in one patient (No.8). Further, the single nucleotide polymorphism (SNP), GCC > GCA (A6A) in SDHB was identified in all patients. This SNP in SDHB is found in nearly all Japanese people [13] . The patient with the novel heterozygous nonsense mutation was a 36-year-old man who had been referred to Hokkaido University Hospital for further examination of a left peri-adrenal lesion. His height was 176 cm, weight was 80 kg, blood pressure was 117/84 mmHg without medication, and pulse rate was 62/min with regular sinus rhythm. Hematological and biochemical tests showed no abnormalities. Serum and urine catecholamines and their metabolite levels are shown in Table 3 . Abdominal computed tomography (CT) scan tensive follow-up is needed for patients who are positive for SDHB mutation. According to Knudson's two-hit theory, patients with a germline mutation should have a somatic mutation or loss of the other allele. In general, somatic point mutations of the SDH gene seem to be very rare. To date, no somatic point mutations have been reported as part of a possible two-hit theory. In contrast, a number of studies reported a somatic deletion mutation at a site proximal to the SDH gene on the wildtype SDH allele in both familial and sporadic tumors [9, [15] [16] [17] . These findings raise the possibility that unknown tumor suppressor genes may be involved in tumorigenesis. In the present case, loss of heterozygosity (LOH) was not examined. A more precise characterization of the somatic alterations associated A novel mutation (Q168X), which is identified in the present study, is described in bold. Abbreviations: fs, frameshift; Ex, exon with SDH mutation will increase our knowledge of the mechanisms underlining tumorigenesis. Although seven patients including five PCC and two abdominal PGL in the present study were strongly suspected of being mutation carriers based on their malignant signs, only one patient with no malignant sign had genetic mutation of SDHB. This result was fewer than expected. A number of studies have reported that patients with abdominal PGL have a higher incidence of mutation of SDHB than those with PCC. For example, an American study [5] reported that 16 of 44 (36.4%) patients with abdominal PGL had SDHB mutation compared to 9 of 313 (2.9%) patients with PCC, and similarly, another French study [6] reported that 17 of 58 (29.3%) patients with thoracoabdominal PGL had SDHB mutation compared to 7 of 314 (2.7%) patients with PCC. Furthermore, an American study [14] which analyzed SDHB mutation in a series of patients with malignant PCC and PGL reported that 12 of 29 (41.4%) patients with abdominal PGL had SDHB mutation compared to 1 of 15 (6.7%) patients with PCC. In the present study, 5 of 7 patients with malignancy had PCC and the other only 2 patients had abdominal PGL, lower rate of SDHB mutation might be due to the difference of tumor origin. Another reason for the lower rate of SDHB mutation may be due to racial differences. As a result, it would be difficult to indicate an association between SDHB mutation and malignancy from this study. On the other hand, a lack of SDHD mutation in the pres- ent study may have been caused by the source of tumor specimens. Because the prevalence of SDHD mutation is known to be higher at head and neck PGL than PCC or abdominal PGL [5, 7, 9] . We did not examine other susceptibility genes, RET, VHL and NF-1, for mutations. Indeed, a VHL-mutated parent and child were included in the present study. However, testing of all susceptibility genes in patients is not recommended from a cost-effectiveness perspective [4] . It is desirable to test for mutations after estimating the pathogenic gene from the patient's clinical characteristics. Several studies in Western countries have revealed associations between genotype and phenotype among patients and indicated the strategy as to which genes should be screened first [4] . However, there is no evidence to support that such correlations are suitable for patients in Asian countries including Japan. We analyzed SDH mutations in 18 patients of which number was too small to conclude the association. Finally, we hope that genotype-phenotype analysis of SDH mutations will lead to the development of an appropriate genetic screening test that would be performed on all patients with PCC and PGL.
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